Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBCBSMA Non-Covered Drug Coverage Policy | OpenPaye…
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - MassachusettsPolicy 433

    Non-Covered Drug List & Non-Covered Formulary Exception

    Customize your policy alerts

    Sign up for Blue Cross Blue Shield - Massachusetts Policy 433 alerts

    Get alerted when Policy 433 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and formulary exception requests for non-covered or non-formulary prescription drugs under applicable BCBSMA commercial pharmacy benefits. It describes coverage authorization criteria, required documentation, formulary alternative trials, and individual consideration for unique clinical circumstances.

    Policy Summary
    PayerBlue Cross Blue Shield - Massachusetts
    PolicyNon-Covered Drug List & Non-Covered Formulary Exception
    Policy CodePolicy 433
    Change TypeNo material change
    Effective DateOct 1, 2026
    Next Review DateN/A
    Key ActionSubmit coverage requests through Formulary Exception Form #434 to BCBSMA Pharmacy Operations.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Commercial pharmacyBenefit scope
    2 alternativesAlternative trials generally required
    24 monthsApproval length
    Highest copaymentException cost share

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Non-coveredListed product status
    U-500Humulin exception

    Non-Covered Drug Exception Coverage Criteria

    Successful Maintenance

    Coverage for a non-formulary drug may be authorized when the Member has been successfully maintained on the current medication and ONE of the following criteria is met:

    ONE of the following

    • The provider establishes, through documented clinical records or medication history, that the Member has been successfully maintained on the current medication regimen, and provides clinical justification that changing to a formulary alternative would result in instability of the medical condition.

      Documentation supporting the clinical justification is required.

    • The Member is actively using a medical device, such as a continuous subcutaneous insulin infusion pump, and requires non-covered diabetic test strips.

    Non-Maintained Member Exception Criteria

    If the Member is not successfully maintained on the requested non-covered medication under the Successful Maintenance criteria, coverage may be authorized only when the following requirements are met:

    All of the following

    • The requested drug is being used for an FDA-approved indication or for an indication supported by current compendia or literature, including AHFS, Micromedex, currently accepted treatment guidelines, peer-reviewed literature, or a peer-reviewed standard of care.
    • At least one of the following applies

      • For a non-covered combination medication, the Member has tried the individual ingredients used together when those ingredients are available and covered on the formulary; or, when the individual ingredients are non-covered, the Member has tried preferred drugs in the same therapeutic class as the individual agents, including over-the-counter alternatives.
      • When formulary alternatives are available, the Member has tried and failed at least two covered alternatives, or one covered alternative when only one formulary alternative is covered within the same therapeutic class for the diagnosis.

        Failure may include inadequate treatment response, intolerance, clinical contraindication, allergic reaction, or adverse reaction. Documentation must support the clinical reason preventing use of the formulary alternative and must identify each alternative's name and strength and provide specifics regarding the treatment failure.

      • When formulary alternatives are available, the Member cannot be switched to a covered formulary alternative because of another specified clinical basis, or switching would cause instability of the medical condition, such as with a narrow therapeutic index medication.

    The non-covered drug list is intended to promote clinically appropriate and cost-effective prescription drug use. Drugs on the list are excluded because safe, comparably effective alternatives are available or because a generic version of the brand-name product is available. Listed alternatives are FDA-approved and widely used and accepted by the medical community to treat the same condition. BCBSMA may require use of formulary alternatives before allowing benefit coverage for a non-covered or non-formulary drug.

    The following drugs and pharmacy products are included on the non-covered drug list, subject to the product-specific exception criteria in this policy: antineoplastic products (including Afinitor, Arimidex, Aromasin, Fusilev, Gleevec, Lutrate Depot, Revlimid, and Vabrinty); antiparasitic and anti-trichomonas products (including Aemcolo, Alinia, Augmentin XR, Flagyl products, Moxatag, Solosec, Tindamax, Xepi, Xifaxan, and Vabrinty); antiviral and hepatitis C products (including Daklinza, Mavyret, Olysio, Sovaldi, Tecnivie, Vosevi, Sitavig, and Zovirax); biologics (including adalimumab products, Adbry, Actemra, Amjevita, Avtozma, Bimzelx, Cibinqo, Cimzia, Cosentyx, Cyltezo, Entyvio, Hulio, Humira, Hyrimoz, Imuldosa, Lemtrada, Omvoh, Orencia, Otulfi, Pyzchiva, Siliq, Simponi, Stelara, Ustekinumab products, Wezlana, Yuflyma, and Yusimry); botulinum toxins (Daxxify, Myobloc, and Xeomin); 5HT agonists and migraine products (including Alsuma, Axert, Frova, Imitrex products, Maxalt, Relpax, Sumavel, Symbravo, Treximet, Zembrace, Reyvow, Symtouch, and Zomig/ZMT); Alzheimer's disease products; anticonvulsants; multiple sclerosis products; pain and opioid products; stimulants and other central nervous system products; dermatologic topical products; diabetic supplies; and oral antidiabetic products. The list also includes the other drug categories and individual products identified in the policy's Non-covered Drug List, including osteoporosis, Paget's disease, and related products.

    Humulin is non-covered except for Humulin U-500.

    Drugs and products in the non-covered categories listed in the policy are excluded from coverage, including growth hormone products; insulins and other diabetes products; miscellaneous oral antidiabetic products; osteoporosis and Paget's disease products; vitamins and minerals; weight-loss products; respiratory products; leukotriene modifiers; and other listed specialty, endocrine, and pharmacy products. This exclusion is subject to the applicable non-covered drug exception criteria.

    Proton pump inhibitor products listed under the PPI category are excluded for Members age 18 years and older, including Aciphex, aspirin/omeprazole, Dexilant, esomeprazole products, First Pantoprazole, Konvomep, Nexium, NapraPAC, omeprazole/sodium bicarbonate, Prilosec, Prevacid 30 mg, Protonix, Yosprala, and Zegerid.

    Submission, Documentation, and Denial Considerations

    Prior Authorization

    Submit Formulary Exception Prior Authorization

    Submit a formulary exception prior authorization request using Formulary Exception Form #434. Physicians may call, fax, or mail the completed form and supporting clinical information to BCBSMA Pharmacy Operations.

    • Pharmacy Operations: 1-800-366-7778
    • Fax: 1-800-583-6289
    • Mail: Blue Cross Blue Shield of Massachusetts Pharmacy Operations Department, 25 Technology Place, Hingham, MA 02043
    Note

    Commercial Pharmacy Benefit Scope

    This policy applies to specified commercial members with pharmacy benefit coverage, including managed care, PPO and Indemnity, MEDEX with an Rx plan, and listed managed major medical and Managed Blue for Seniors plans with a custom BCBSMA formulary.

    • Applies to Commercial Members
    • Pharmacy (Rx) benefit; not the MED benefit

    Policy Rationale and Context

    BCBSMA identifies non-covered drugs as products for which safe, comparably effective alternatives or generic equivalents are available. The alternatives are FDA-approved and widely used and accepted by the medical community for treating the same condition. The formulary exception process may allow coverage when the member is successfully maintained on the requested medication, cannot safely or clinically switch, meets required alternative-trial criteria, or has another recognized clinical circumstance.

    Initial Therapy Exception

    Initial Therapy Exception

    For a member not successfully maintained on the requested drug, coverage may be considered when the indication, applicable combination-drug requirements, and an exception pathway are supported.

    Initial non-covered drug exception

    • Supported indication: The requested drug is for an FDA-approved indication or an indication supported by current literature compendia, such as AHFS or Micromedex, currently accepted treatment guidelines, or peer-reviewed standard of care.
    • Combination medication trial: For a non-covered combination medication, the member has had a trial of the individual ingredients used together when they are available and covered on the formulary, or preferred drugs in the same therapeutic class when the individual agents are non-covered, including over-the-counter alternatives.
    • ONE applicable exception pathway

    Successful Maintenance Continuation

    Successful Maintenance Continuation

    A non-formulary drug may be authorized for a member already maintained on therapy when ONE of the following criteria is met.

    ONE of

    • Successful maintenance: The provider documents through clinical records or medication history that the member has been successfully maintained on the current medication regimen and provides clinical justification that changing to a formulary alternative would result in instability of the medical condition.

      Documentation supporting the clinical justification is required.

    • Medical-device pathway: The member is actively using a medical device, such as a continuous subcutaneous insulin infusion pump, and requires non-covered diabetic test strips.

    Formulary Alternative Trial Requirements

    StepRequirementAcceptable reasons for failureDocumentation required
    1Try and fail at least 2 covered formulary alternatives, or 1 covered alternative when only one formulary alternative is covered within the same therapeutic class for the diagnosis.Inadequate treatment response, intolerance, clinical contraindication, allergic reaction, or adverse reaction.Provide the names and strengths of alternatives tried and failed, specific treatment-failure details, and the clinical reason preventing a trial of a covered alternative, when applicable.
    Policy Summary
    PayerBlue Cross Blue Shield - Massachusetts
    PolicyNon-Covered Drug List & Non-Covered Formulary Exception
    Policy CodePolicy 433
    Change TypeNo material change
    Effective DateOct 1, 2026
    Next Review DateN/A
    Key ActionSubmit coverage requests through Formulary Exception Form #434 to BCBSMA Pharmacy Operations.
    SourceLink
    On This Page
    Non-Covered Drug Exception Coverage CriteriaSubmission, Documentation, and Denial ConsiderationsPolicy Rationale and ContextInitial Therapy ExceptionSuccessful Maintenance ContinuationFormulary Alternative Trial Requirements

    Documentation supporting the clinical basis is required before approval.

  1. The requested non-covered drug is needed because of a drug supply shortage.
  2. A brand-name drug is requested when an FDA-approved generic is a formulary alternative.

    Documentation supporting trial and failure or contraindication of the generic is required for approval.

  3. Step Therapy

    Document Trial and Failure of Alternatives

    When the member is not successfully maintained on the requested non-covered medication, document the required trial and failure of covered formulary alternatives when available. Generally, at least two covered alternatives must have been tried and failed, or one if only one formulary alternative is covered for the diagnosis within the therapeutic class.

    • Acceptable reasons may include inadequate response, intolerance, contraindication, allergy, or adverse reaction.
    • Document the clinical reason preventing an alternative trial when a trial cannot be performed.

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: documentation

    Denial Risk

    Failure to Establish Exception Criteria

    Exception requests may be denied when safe, comparably effective FDA-approved alternatives or generic equivalents are available and the required exception criteria are not established.

    • Support any inability to use a formulary alternative or any risk of instability with a clinical rationale.
    • A non-covered drug may also qualify when the requested product is affected by a drug supply shortage, subject to review.
    Denial Risk

    Unsupported Indication

    The requested drug must be used for an FDA-approved indication or an indication supported by recognized compendia, current treatment guidelines, peer-reviewed literature, or an accepted standard of care.

    • Examples of recognized sources include AHFS, Micromedex, and currently accepted treatment guidelines.
    Step Therapy

    Combination-Drug Requirements Not Met

    For a non-covered combination medication, document trials of the individual ingredients used together when those ingredients are available and covered on the formulary. If the individual ingredients are non-covered, address preferred drugs in the same therapeutic class, including over-the-counter alternatives.

    • The required individual-ingredient or preferred-drug trials must be addressed before the combination product can be considered.
    Denial Risk

    Requested Product Is Listed as Non-Covered

    Products appearing on the non-covered drug list are not covered unless an applicable formulary exception is authorized. The list includes drugs, biologics, diabetic supplies, topical products, and other pharmacy products across listed therapeutic categories.

    • Confirm whether the requested product is listed as non-covered before submitting.
    • Coverage is generally excluded because safe, comparably effective alternatives or generic versions are available.
    Denial Risk

    Product-Specific Exception Requirements

    Review the product-specific limitations and exceptions in the non-covered list before requesting an exception. Product categories may include diabetes supplies, growth hormone, insulin, and other products subject to listed restrictions.

    • Insulin-related restrictions include listed products such as Admelog, Apidra, Basaglar, Fiasp, Humalog, and Humulin, with the stated exception for Humulin U500.
    • Non-covered diabetic test strips may be considered when the member actively uses a qualifying insulin pump, subject to the successful-maintenance criteria.
    Denial Risk

    Non-Covered Drug List Review

    A requested product may be denied when it appears on the non-covered drug list or falls within a listed non-covered category, including products identified in the drug list's therapeutic-category sections.

    • Verify the exact product, strength, formulation, and category against the current non-covered list.
    • Listed categories include prescription drugs, biologics, topical products, diabetic supplies, and other pharmacy products.
    Denial Risk

    Age-Specific PPI Exclusion

    Certain proton pump inhibitor products are excluded for members 18 years and older. Requests for products in this age-specific PPI exclusion require review against the applicable exception criteria.

    • The listed PPI products include Aciphex, aspirin/omeprazole, Dexilant, esomeprazole products, First Pantoprazole, Konvomep, Nexium, omeprazole/sodium bicarbonate, Prilosec, Prevacid 30 mg, Protonix, Yosprala, and Zegerid.
    Formulary alternative trial and failure: If formulary alternatives are available, the member has tried and failed the required covered alternatives.At least 2 covered alternatives, or 1 if only one formulary alternative is covered in the same therapeutic class for the given diagnosis

    Failure may include inadequate treatment response, intolerance, clinical contraindication, allergic reaction, or adverse reaction.

  4. Clinical inability to switch: The member cannot be switched to a covered formulary alternative because of another specified clinical basis or because switching would cause instability of the medical condition, such as with a narrow therapeutic index medication.

    Documentation supporting the clinical basis is required before approval.

  5. Drug supply shortage: The requested non-covered drug is needed because of a drug supply shortage.
  6. Brand versus generic: When a brand is requested and an FDA-approved generic is a formulary alternative, documentation supports trial, failure, or contraindication of the generic.